Charles Schwab’s TCR2 Therapeutics Inc. Common Stock TCRR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-22,638
| Closed | -$34K | – | 3732 |
|
|
2023
Q1 | $34K | Buy |
+22,638
| New | +$30.5K | ﹤0.01% | 3427 |
|
|
2022
Q3 | – | Sell |
-177,081
| Closed | -$514K | – | 3566 |
|
|
2022
Q2 | $514K | Sell |
177,081
-50,448
| -22% | -$124K | ﹤0.01% | 3070 |
|
|
2022
Q1 | $628K | Sell |
227,529
-7,724
| -3% | -$24.3K | ﹤0.01% | 3034 |
|
|
2021
Q4 | $1.1M | Buy |
235,253
+3,202
| +1% | +$20K | ﹤0.01% | 2874 |
|
|
2021
Q3 | $1.98M | Buy |
232,051
+37,480
| +19% | +$530K | ﹤0.01% | 2706 |
|
|
2021
Q2 | $3.19M | Buy |
194,571
+6,555
| +3% | +$132K | ﹤0.01% | 2563 |
|
|
2021
Q1 | $4.15M | Buy |
188,016
+28,429
| +18% | +$775K | ﹤0.01% | 2381 |
|
|
2020
Q4 | $4.94M | Buy |
159,587
+779
| +0.5% | +$19.7K | ﹤0.01% | 2226 |
|
|
2020
Q3 | $3.23M | Buy |
158,808
+61,159
| +63% | +$1.07M | ﹤0.01% | 2300 |
|
|
2020
Q2 | $1.5M | Buy |
97,649
+16,443
| +20% | +$190K | ﹤0.01% | 2516 |
|
|
2020
Q1 | $629K | Buy |
81,206
+1,786
| +2% | +$21.9K | ﹤0.01% | 2636 |
|
|
2019
Q4 | $1.14M | Buy |
79,420
+986
| +1% | +$15.2K | ﹤0.01% | 2557 |
|
|
2019
Q3 | $1.18M | Buy |
78,434
+54,070
| +222% | +$842K | ﹤0.01% | 2523 |
|
|
2019
Q2 | $349K | Buy |
+24,364
| New | +$389K | ﹤0.01% | 2968 |
|
Charles Schwab's TCRR Position: Q2 2023 in Review
Charles Schwab sold out of TCR2 Therapeutics Inc. Common Stock (TCRR) in Q2 2023, closing a stake of 22,638 shares — an estimated $34K sold.
Charles Schwab first reported a position in TCRR in Q2 2019 and held it in 14 quarters. The position peaked at $4.94M in Q4 2020. 0 funds tracked by Wall St. Rank hold TCRR as of Q2 2023.
- Charles Schwab reported no remaining TCR2 Therapeutics Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
- Charles Schwab sold 22,638 TCR2 Therapeutics Inc. Common Stock shares in Q2 2023, an estimated $34K.
- Charles Schwab first reported a position in TCR2 Therapeutics Inc. Common Stock in Q2 2019 and held it in 14 quarters.
- Charles Schwab's TCR2 Therapeutics Inc. Common Stock position peaked at $4.94M in Q4 2020.
- 0 funds tracked by Wall St. Rank held TCR2 Therapeutics Inc. Common Stock as of Q2 2023.
Based on Charles Schwab's 13F filing for Q2 2023, filed 10 Aug 2023.